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ABSTRACT
ObjectiveToassesstheefficacy,acceptability,andsafety
of a topical alkane vapocoolant in reducing pain during
intravenous cannulation in adults.
DesignRandomiseddoubleblindplacebocontrolledtrial.
SettingEmergencydepartmentofametropolitanteaching
hospital.
Participants 201 adult patients (54% male), mean (SD)
age 58.2 (19.5) years, who required intravenous
cannulation.
Interventions Less than 15 seconds before cannulation,
theskinareawassprayedwitheitherwater(control,n=98)
or vapocoolant (intervention, n=103), from a distance of
12cmfor2seconds.Theinterventionspraywasablendof
propane, butane, and pentane.
Main outcome measures Pain with cannulation and
discomfort with spray, measured with a 100 mm visual
analogue scale.
Results Groups did not differ significantly in age, sex,
indication for or site of cannulation, cannula size, or who
cannulated the patient (P>0.05). Median (interquartile
range) pain scores for cannulation in the control and
intervention groups were 36 (19-51) and 12 (5-40) mm,
respectively (P<0.001), and 59 (60%) and 33 (32%)
reported pain scores ≥30 mm (P<0.001). Scores for spray
discomfortalsodifferedsignificantly(P<0.001)becauseof
skewing to the right within the intervention group. The
median discomfort scores, however, were 0 mm in both
groups.Successratesforfirstcannulationattemptdidnot
differ between groups (P=0.39). Thirty four (39%) and 62
(62%) patients said they would choose the spray they
receivedforanalgesiainthefuture(P=0.002).Atfollow-up
at five days, two patients in the intervention group
reported transient skin redness.
Conclusions Topical alkane vapocoolant spray is
effective, acceptable, and safe in reducing pain with
peripheral intravenous cannulation in adults in the
emergency department.
Trial registration Australian Clinical Trials
ACTRN12607000470493.
INTRODUCTION
Asabouthalfofpatientsreportmoderatetoseverepain
with cannulation and anxiety before the procedure,
administration of local anaesthetic might be justified.
1
On a 100 mm visual analogue scale pain scores in
untreated adults ranged from 24 mm to 38 mm.
1-3
Intradermal injection of lidocaine is commonly used
for analgesia.
4 This effectively reduces pain
23 by
clinically important amounts.
5 The injection itself,
however, is painful,
3 and, theoretically, there is an
increased risk of needle stick injury. Additionally,
reports are divided on whether local tissue distortion,
causedbytheinjection,increases
3orhasnoeffecton
12
the rate of cannulation failure.
Another strategy is the application of topical local
anaesthetic. These agents must penetrate the stratum
corneum barrier,
67 which necessitates application
times of at least 45 minutes for Emla (lidocaine 2.5%
and prilocaine 2.5%)
8 and 30 minutes for Ametop (4%
tetracaine).
9 In emergency departments, such applica-
tion times are often unacceptable as immediate
cannulation is often required.
Less than half of medical and surgical doctors use
localanaestheticforinsertionoflargeboreintravenous
cannulas.
10 Furthermore, for the most commonly used
cannula (size 20 gauge), less than 20% of all doctors
used any local anaesthetic.
10 Another study reported
that 35% of junior doctors had previously used local
anaestheticforcannulationbuttheircurrentrateofuse
was only 6%.
4
Topical vapocoolant sprays can produce immediate
skin anaesthesia. Commonly used vapocoolants
includeethylchloride,fluorohydrocarbon,andalkane
mixtures (butane, propane, and pentane). Alkane
vapocoolant sprays are primarily used to provide
rapid pain relief from acute muscular injuries. Rapid
evaporation of the volatile liquid spray from the skin
surface causes a drop in temperature and results in
temporary interruption of pain sensation, possibly
through desensitisation of pain receptors or activation
of ion channels involved in pain transmission.
11
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tially convenient and effective anaesthetic for intra-
venous cannulation.
Previous studies of vapocoolant sprays for reducing
pain with intravenous cannulation in adults have
shown inconsistent results. Four randomised con-
trolled trials have been reported. Two showed ethyl
chloride to be effective,
23while two others found ethyl
chloride
1 and fluorohydrocarbon,
12 respectively, to be
ineffective. Methods in these studies varied, including
variation in cannula size, duration and distance of
spray, small sample sizes, and lack of blinding.
We assessed the efficacy, acceptability, and safety of
a topical alkane vapocoolant spray for reducing pain
with intravenous cannulation in adults by comparing
its effects with a control (water) spray.
METHODS
Study design
ThetrialtookplacefromNovember2007toMay2008.
It was a randomised double blind placebo controlled
clinical trial set in a mixed (adult and paediatric)
emergency department that treated about 55000
patients a year.
Patients were included if they were aged ≥18 and
needed intravenous cannulation. Exclusion criteria
were refusal to participate, inability to provide
informed consent (non-English speaking, altered
mental state, severe illness, urgent need for cannula-
tion), moderate to severe discomfort or pain, skin
disease associated with cold intolerance (such as
Raynaud’s phenomenon), known allergy to spray
contents, peripheral neuropathy or numbness, parent-
eral analgesia within the previous four hours, and the
use of other local anaesthesia.
Recruitment
We enrolled a convenience sample comprising con-
secutive patients who met the entrance criteria during
periods when the principal investigator was present in
the emergency department (mainly 9 am to 5 pm on
weekdays). The emergency department staff notified
the principal investigator of patients who required
cannulation. Patients who met the entrance criteria
received a verbal and written explanation of the study
and gave written consent to participate.
Randomisation
Each enrolled patient was then assigned the next
sequentially ordered study pack. These contained all
the documents for data collection and a sealed
envelope containing a note that advised the group to
which the patient had been randomised. Patients were
block randomised (blocks of six) by an independent
pharmacist using a computerised random number
generator. Until after informed consent had been
obtained,onlythepharmacistknewtherandomisation
status. At that time, the principal investigator opened
the sealed envelope and prepared to administer the
assigned spray. The patients, their carers in the
emergency department, and independent emergency
department staff who collected outcome data were all
blinded to the randomisation status.
Intervention and control sprays
The vapocoolant (intervention) spray was CO
LD Spray, manufactured by DIFA Chemical Indus-
tries for Alpha First Aid Supplies. It is a propane,
butane, and pentane blend, with an added fragrance,
andissuppliedinastandard(about20cmlong,250gin
weight)handheldpressurisedspraycan.Itisregistered
withtheTherapeuticGoodsAdministration,Australia,
for the first aid treatment of muscular pain and other
injuries. One 250 g can costs $A13.90 (£6, €7) and
contains about 70 administrations.
Thecontrol(placebo)spraywasEvianEauMinerale
Naturelle, a pure water spray with hydrocarbon
propellant. This product is used to provide a cooling
mistforcomfortduringhotweather.Itisalsopackedin
ahandheldpressurisedspraycanofaboutthesamesize
as the intervention spray.
Spray application
The intervention and control spray cans were masked
in white paper and labelled A and B. Because of the
slight differences in the two sprays (variable transient
skin blanching, jet force, and trajectory) the principal
investigator(sprayadministrator)couldnotbeblinded.
Table 1 |Baseline characteristics of patients undergoing
cannulation according to allocation to control (water spray)
or intervention (vapocoolant spray) group. Figures are
numbers (percentages) of patients unless specified
otherwise
Control (n=98) Intervention (n=103)
Mean (SD) age (years) 56.3 (20.0) 59.9 (19.0)
Men 52 (53) 57 (55)
Main reason for cannulation:
Blood test 68 (69) 65 (63)
Drug administration 19 (19) 24 (23)
Fluid administration 7 (7) 9 (9)
Blood transfusion 1 (1) 4 (4)
Unspecified 3 (3) 1 (1)
Cannulation site:
Cubital fossa 45 (46) 56 (54)
Dorsum of hand 29 (30) 24 (23)
Radial side of wrist 10 (10) 4 (4)
Radial side of forearm 7 (7) 11 (11)
Other 7 (7) 8 (8)
Cannula size:
18 gauge 13 (13) 12 (12)
20 gauge 77 (79) 84 (82)
22 gauge 8 (8) 7 (7)
Who cannulated patient:
Nurse 76 (78) 79 (77)
Resident 6 (6) 11 (11)
Medical student 8 (8) 4 (4)
Registrar 5 (5) 3 (3)
Consultant 3 (3) 4 (4)
Intern 0 (0) 2 (2)
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might have precluded effective blinding. A simulta-
neousonesecondsprayfrombothcans,directedaway
fromstaff,wasundertakenabout30secondsbeforethe
allocated spray administration thus a slight fragrance
was generated regardless of the nature of the spray
administered.
A blinded member of emergency department staff
identified a suitable vein for cannulation. The over-
lyingskinwaswipedwithanalcoholswabandallowed
to dry, as per standard operating procedures. The
principal investigator then administered the allocated
spray from a distance of about 12 cm for two seconds.
This technique avoided “frosting up” of vapocoolant
on the skin. Liquid spray on the skin was allowed to
evaporate for up to 10 seconds. The area was again
wiped with an alcohol swab and cannulation pro-
ceededimmediately.Cannulationhadtobecarriedout
within 15 seconds of administration of the spray.
Outcome measures
Ourprimaryoutcomemeasurewaspainwithcannula-
tion. Secondary measures were discomfort with the
spray on administration, success rate of cannulation,
willingness of the patient to choose the allocated spray
in the future, the patients’ guess at randomisation
status, and unexpected events.
We used separate visual analogue scales to assess
pain with cannulation and discomfort with the spray.
Eachcompriseda100mmhorizontallinelabelled“no
pain”attheleftendand“worstpainimaginable”atthe
right. About one minute after cannulation, the patient
marked their perceived level of pain with cannulation,
followed by level of initial discomfort with the spray.
Comparedwithverbaldescriptorscalesandnumerical
ratingscales
13thevisualanaloguescaleisvalidatedasa
highlydiscriminantmethodofassessingpainandhasa
high test-retest repeatability.
14 After we collected data
on pain and discomfort, we asked the patient about
their willingness to choose the allocated spray in the
future and to guess at their randomisation status.
A blinded assistant (emergency department physi-
cian or nurse) not involved with the patient’s care
collected all outcome data, independent of the
principal investigator. The principal investigator
recorded only patients’ demographics, reasons for
cannulation, site and success of cannulation, size of
cannula, and who cannulated the patient.
Theprincipalinvestigatorattemptedtofollow-upall
patients five days after cannulation, either by visiting
the wardor by telephoneat home.Patientswere asked
toprovideadescriptionofanyunexpectedeventsthey
experienced at the cannulation site. The investigator
also asked specific closed questions (presence and
timing of any pain, redness, swelling, and itching). At
leastthreeattemptsweremadetocontacteachpatient.
Statistical analysis
The mean pain score with cannulation has been
reported as 30 mm (SD 25).
1 Reports of clinically
important reductions in pain scores range from 9-
18 mm.
515-17 Ourstudywasconservatively poweredto
detecta10mmdifferencebetweenmeanpainscoresin
the groups (30 mm v 20 mm, respectively). At least 98
patients were required in each group (power 0.8, level
of significance 0.05).
We compared the scores for cannulation pain
and spray discomfort using the Mann-Whitney
U test as neither variable was normally distributed
(Kolmogorov-Smirnov test P=0.011 and P<0.001,
respectively). We used the Kolmogorov-Smirnov test
to compare age distributions and χ
2 (with Yates’s
correction) to compare categorical data. Unexpected
events are reported descriptively. All data were
analysed with the intention to treat principle and
SPSS statistical software (SPSS, Chicago, IL) (level of
significance 0.05).
RESULTS
Study population
Of 304 patients assessed for enrolment, 201 were
randomised: 98 to the control group and 103 to the
intervention group (fig 1). The groups did not differ
significantly (P>0.05) in age, sex, reason for cannula-
tion, cannulation site, cannula size, or who cannulated
the patients (table 1). There were, however, five
protocol violations. For one patient in the control
group and two in the intervention group, the cannula-
tion site was slightly away from the site sprayed. Also,
for two patients in the intervention group, incomplete
preparationresultedinadelayofmorethan15seconds
between spraying and cannulation.
Study outcomes
Table 2showsthemainoutcomemeasures.Patientsin
the intervention group reported significantly lower
pain scores with cannulation; their median pain score
was one third that of the control group. There were
also significantly fewer patients in the intervention
group who reported a pain score of ≥30 mm. Figure 2
presents the pain score distributions graphically.
Excluded (n=103):
  Refused to participate (n=24)
  Did not meet entrance criteria (n=79)
Protocol violations (n=1)
Loss to follow-up at 5
  days (n=25)
Protocol violations (n=4)
Loss to follow-up at 5
  days (n=20)
Assessed for eligibility (n=304)
Enrolled (n=201)
Randomised to control
(water spray) (n=98)
Randomised to intervention
(vapocoolant spray) (n=103)
Analysed (n=98)
(none excluded)
Analysed (n=103)
(none excluded)
Fig 1 | Recruitment and flow of participants though trial
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with median discomfort scores of zero in both groups.
However,23(24%)and50(49%)patientsinthecontrol
and intervention groups, respectively, reported a
discomfort score of more than zero. Hence, skewing
of the scores to the right in the intervention group
resulted in a significant difference between the groups.
Significantly more patients in the intervention group
reported that they would choose the spray they
received if they had a choice in the future. The nature
of the spray did not affect success rates of cannulation.
Significantly more patients in the control group
correctlyguessedthenatureofthespraytheyreceived.
Despite this, almost a third and a half of patients in the
control and intervention groups, respectively, did not
correctly guess which spray they received. This
suggests a considerable level of blinding in both
groups.
Atfivedaysaftercannulation,73(75%)and83(81%)
patients in the control and intervention groups,
respectively, were followed up. Of these, two patients
in the intervention group reported transient redness at
the site sprayed. No other unexpected events were
reported.
DISCUSSION
Anecdotally, alkane vapocoolant sprays are used in
some UK and Irish emergency departments to
decrease pain with intravenous cannulation. There
are few reports, however, regarding the use of these
agents for this indication. We have shown that,
compared with control patients, those who received
alkane vapocoolant had a 24 mm lower median pain
score (18 mm lower mean) and significantly fewer had
painscores≥30mm.Alkanevapocoolantspraybefore
intravenous cannulation does, therefore, result in a
meaningful decrease in the pain experienced.
There was a significant difference between the
discomfort of placebo and vapocoolant application.
Themediandiscomfortscoreinbothgroups,however,
was zero, and the absolute amount of discomfort from
the vapocoolant was small. Furthermore, almost two
thirds of patients who received the vapocoolant spray
would choose this treatment in the future to reduce
cannulation pain compared with about one third of
patients who received the placebo. This difference
probably reflects patients’ satisfaction with the spray
administered.
Unexpectedeventswiththevapocoolantspraywere
minor and seen in only two patients. It is not known
whethertheseeventswereattributabletothevapocoo-
lant itself, and the difference between groups might
have been attributable to the higher rate of follow-up
within the vapocoolant group. Notably, our event rate
was low compared with those reported for tetracaine
(erythema 34%, pruritus 6%),
18 Emla (erythema 6%),
18
and lidocaine (erythema 13%, swelling 53%).
1
Otherrisksassociatedwithvapocoolantarelikelyto
beminimal.Likemanyothervapocoolants,theonewe
examined is flammable and its use around heat or
ignition sources is not recommended.
11 The short
duration of spray (two seconds) and the lack of heat or
ignition sources in the immediate vicinity, however, is
likely to ensure its safety. The manufacturer recom-
mendsaspraytimeofnolongerthanfivesecondsanda
distance of at least 12 cm to avoid frostbite.
11 We had
trialled a range of spray times (while spraying from 12
cm) and frosting, with the chance of frostbite, did not
occur with a duration of two seconds. The risk of local
atmosphericpollutionisalsolikelytobeminimalgiven
the short and focused administration.
Though vasoconstriction from cooling might
increase the difficulty of cannulation, we found no
significant difference in success rates of cannulation
between the two groups. Lidocaine has been reported
to increase the failure of cannulation because of tissue
distortion,
3 and Emla can cause vasoconstriction,
1819
which can increase difficulties with cannulation.
18
Strengths and limitations
Selection bias might have occurred if patients who
refusedorwereexcludeddifferedfromthoseenrolled.
The periods when the principal investigator was
available for enrolment were limited. While this
extended the length of the study, enrolment of
consecutive patients during enrolment periods prob-
ablyminimisedselectionbias.Only24patientsrefused
to take part, and there is no reason to believe that
excluded patients differed substantially. Harris et al
reported that the perception of cannulation pain is
unaffected by the presence or absence of other painful
conditions.
20 Hence, selection bias is unlikely to have
affected the results. Although the baseline character-
istics of the two groups were similar, we did not
Table 2 |Outcome measures in patients undergoing cannulation according to allocation to
control(waterspray)orintervention(vapocoolantspray). Figuresare numbers (percentages) of
patients unless specified otherwise
Control (n=98) Intervention (n=103) P value
Median (IQR) pain with cannulation 36 (19-51) 12 (5-40) <0.001
Cannulation pain ≥30 mm 59 (60) 33 (32) <0.001
Median (IQR) discomfort with spray 0 (0-0) 0 (0-11) <0.001
Successful cannulation 73 (75) 83 (81) 0.390
Future choice of same spray* 34 (39) 62 (62) 0.002
Correct guess at nature of spray 68 (69) 56 (54) 0.001
IQR=interquartile range.
*Data missing for 10 in control group and three in intervention group.
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Fig 2 | Distribution of pain scores with cannulation
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threshold and needle anxiety. The large sample size
and the randomisation used, however, probably
distributed these confounders evenly between the
groups.Wetookconsiderableefforttoensureblinding
of patients, though about two thirds of patients in the
control group guessed their randomisation status,
which might have resulted in measurement bias. This
isunlikely tohave resultedfromthe lackof blindingof
the sprayers, as we used an independent blinded
assessor to collect pain scores and all other outcome
data.Ideally,allassessmentswouldhavebeenmadeby
the same blinded assessor to ensure consistency.
However, all assessors were familiar in the use of the
visualanaloguescale,andanybiasinvariationbetween
them is likely to have been balanced between the two
groups. As the telephone follow-up provided limited
data, it is difficult to compare these data with those of
others. Its purpose, however, was to screen for a range
of unexpected events rather than to determine their
exact nature. As unexpected events were rare, minor,
and transient, a more detailed examination would not
have been useful.
Comparison with other studies
Althoughmethodsdiffered,ourfindingsareconsistent
with those of two studies that examined ethyl chloride
for the same indication.
23In contrast, other vapocoo-
lant trials of ethyl chloride
1 and fluorohydrocarbon
12
did not show significant pain relief. The ethyl chloride
study, however, was not blinded, used a larger sized
cannula (18 gauge rather than 20 gauge), sprayed the
vapocoolant from 25 cm until a layer of frosting was
seen,
1andhadavapocoolantgroupcomprisingonly30
patients.Thefluorohydrocarbonstudy,whichwasalso
undertaken in an emergency department setting, was
not blinded and was probably underpowered as the
standard deviation used in the sample size calculation
wasconsiderablysmallerthanthatobservedinthedata
collected.
12 Small sample sizes probably limited the
findings of earlier vapocoolant studies. Indeed, the
largest group analysed in any of these studies was 47
patients.
12 Hence, strengths of our study are the use of
blinding and the considerably larger sample size.
Recommendations
Notwithstanding these limitations, our findings indi-
cate that vapocoolant spray might be useful for
decreasing pain with cannulation. If further trials
confirm our findings, consideration should be given
foritsroutineuse.Trialscomparingvapocoolantspray
with intradermal lidocaine are recommended and
should include the additional outcomes of cost,
application time (preparation, administration, onset
of effect), and convenience.
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WHAT IS ALREADY KNOWN ON THIS TOPIC
There have been conflicting reports from small unblinded studies on the efficacy of
vapocoolant sprays to reduce pain with intravenous cannulation
Some clinicians use these agents for this indication
WHAT THIS STUDY ADDS
Alkanevapocoolantsprayresultsinsignificantreductionsinpainwithcannulationandissafe
and acceptable to patients
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